Combination Therapy for Treatment of Infections with

Clinical Microbiology Reviews
25, 450-470
DOI: 10.1128/cmr.05041-11

Citation Report

#	Article	IF	Citations
1	Less Is More. JAMA Pediatrics, 2013, 167, 903.	6.2	41
2	Multidrug-Resistant Bacteria in Organ Transplantation: An Emerging Threat with Limited Therapeutic Options. Current Infectious Disease Reports, 2013, 15, 504-513.	3.0	13
3	Experimental evolution as an efficient tool to dissect adaptive paths to antibiotic resistance. Drug Resistance Updates, 2013, 16, 96-107.	14.4	42
4	Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 3-11.	0.5	68
5	Treatment of carbapenem-resistantKlebsiella pneumoniae: the state of the art. Expert Review of Anti-Infective Therapy, 2013, 11, 159-177.	4.4	139
6	Update in Pulmonary Infections 2012. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1061-1066.	5.6	2
7	Combination approaches to combat multidrug-resistant bacteria. Trends in Biotechnology, 2013, 31, 177-184.	9.3	480
8	Empirical antimicrobial therapy for critically ill patients with Acinetobacter baumannii bacteremia: Combination is better. Journal of Microbiology, Immunology and Infection, 2013, 46, 397-398.	3.1	6
10	Megalin Contributes to Kidney Accumulation and Nephrotoxicity of Colistin. Antimicrobial Agents and Chemotherapy, 2013, 57, 6319-6324.	3.2	84
11	Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Critical Care, 2013, 17, R265.	5.8	33
12	In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 299-303.	0.9	22
13	Escherichia coli in Europe: An Overview. International Journal of Environmental Research and Public Health, 2013, 10, 6235-6254.	2.6	294
14	Robustness and Plasticity of Metabolic Pathway Flux among Uropathogenic Isolates of Pseudomonas aeruginosa. PLoS ONE, 2014, 9, e88368.	2.5	60
15	Beneficial Antimicrobial Effect of the Addition of an Aminoglycoside to a Î²-Lactam Antibiotic in an E. coli Porcine Intensive Care Severe Sepsis Model. PLoS ONE, 2014, 9, e90441.	2.5	15
16	In Vitro Antibiofilm Efficacies of Different Antibiotic Combinations with Zinc Sulfate against Pseudomonas aeruginosa Recovered from Hospitalized Patients with Urinary Tract Infection. Antibiotics, 2014, 3, 64-84.	3.7	21
17	Evolution of antimicrobial resistance of <i>Salmonella enteritidis</i> (1972â€“2005). Onderstepoort Journal of Veterinary Research, 2014, 81, e1-e6.	1.2	6
18	In vitro antimicrobial evaluation of two indigenous functional food-plants (Chenopodium album and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf African Journal of Microbiology Research, 2014, 8, 3612-3616.	0.4	0
19	Efficacy of Ciprofloxacin-Clarithromycin Combination Against Drug-Resistant Pseudomonas aeruginosa Mature Biofilm Using In Vitro Experimental Model. Microbial Drug Resistance, 2014, 20, 575-582.	2.0	15

#	Article	IF	Citations
20	Antibiotic stewardship in the intensive care unit. Critical Care, 2014, 18, 480.	5.8	252
21	Current concepts in combination antibiotic therapy for critically ill patients. Indian Journal of Critical Care Medicine, 2014, 18, 310-314.	0.9	77
22	Computational Analyses of Synergism in Small Molecular Network Motifs. PLoS Computational Biology, 2014, 10, e1003524.	3.2	21
23	Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit?. Diagnostic Microbiology and Infectious Disease, 2014, 80, 239-259.	1.8	34
24	Burden of Antibiotic Resistance in Common Infectious Diseases: Role of Antibiotic Combination Therapy. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, ME05-8.	0.8	20
25	Pseudomonas aeruginosaAmpR: an acute-chronic switch regulator. Pathogens and Disease, 2014, 73, n/a-n/a.	2.0	55
26	Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. International Journal of Antimicrobial Agents, 2014, 44, 552-556.	2.5	22
27	A Critical Evaluation of Healthcare-Associated Pneumonia and the Need for Anti-pseudomonal Therapy, Including Double Coverage. Current Emergency and Hospital Medicine Reports, 2014, 2, 196-204.	1.5	0
28	'Evolution-Proofing' Antibacterials. Evolution, Medicine and Public Health, 2014, 2014, 134-135.	2.5	7
29	Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Upsala Journal of Medical Sciences, 2014, 119, 149-153.	0.9	124
30	Prediction of resistance development against drug combinations by collateral responses to component drugs. Science Translational Medicine, 2014, 6, 262ra156.	12.4	150
31	Treatment of Multidrug-Resistant Gram-Negative Infections in Children. Clinical Infectious Diseases, 2014, 58, 1439-1448.	5.8	122
32	Role of Pseudomonas aeruginosa AmpR on Î²-lactam and non-Î²-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics. Journal of Medical Microbiology, 2014, 63, 544-555.	1.8	33
33	Therapeutic strategies to combat antibiotic resistance. Advanced Drug Delivery Reviews, 2014, 78, 14-27.	13.7	293
34	What is new in the use of aminoglycosides in critically ill patients?. Intensive Care Medicine, 2014, 40, 1553-1555.	8.2	11
35	Treatment option for sepsis in children in the era of antibiotic resistance. Expert Review of Anti-Infective Therapy, 2014, 12, 1237-1252.	4.4	14
36	Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14494-14499.	7.1	215
37	Pharmacotherapy for hospital-acquired pneumonia. Expert Opinion on Pharmacotherapy, 2014, 15, 775-786.	1.8	5

#	Article	IF	Citations
38	Combating multidrug-resistant Gram-negative bacterial infections. Expert Opinion on Investigational Drugs, 2014, 23, 163-182.	4.1	106
39	Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Current Treatment Options in Infectious Diseases, 2014, 6, 425-438.	1.9	5
40	A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa. Journal of Medical Microbiology, 2014, 63, 945-955.	1.8	49
41	PrtR Homeostasis Contributes to Pseudomonas aeruginosa Pathogenesis and Resistance against Ciprofloxacin. Infection and Immunity, 2014, 82, 1638-1647.	2.2	44
42	Empiric Combination Therapy for Gram-Negative Bacteremia. Pediatrics, 2014, 133, e1148-e1155.	2.1	30
43	Carbapenemâ€resistant Enterobacteriaceae: biology, epidemiology, and management. Annals of the New York Academy of Sciences, 2014, 1323, 22-42.	3.8	173
45	Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia. International Journal of Antimicrobial Agents, 2014, 43, 391-393.	2.5	4
46	When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing. Journal of Clinical Microbiology, 2014, 52, 4124-4128.	3.9	294
47	Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clinical Microbiology and Infection, 2014, 20, 862-872.	6.0	281
48	Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opinion on Therapeutic Targets, 2014, 18, 851-861.	3.4	22
49	Additivity and synergy between an antimicrobial peptide and inhibitory ions. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2234-2242.	2.6	15
50	NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo Efficacy. Antimicrobial Agents and Chemotherapy, 2014, 58, 2657-2664.	3.2	43
52	Hydroxybenzaldoximes Are <scp>D</scp>â€GAPâ€Competitive Inhibitors of E. coli 1â€Deoxyâ€<scp>D</scp>â€Xyluloseâ€5â€Phosphate Synthase. ChemBioChem, 2015, 16, 1771-1781.	2.6	18
53	Optimizing dosing of antibiotics in critically ill patients. Current Opinion in Infectious Diseases, 2015, 28, 497-504.	3.1	41
54	Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Pharmacotherapy, 2015, 35, 949-962.	2.6	271
55	Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children. Pediatric Infectious Disease Journal, 2015, 34, 1203-1206.	2.0	3
56	New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Current Opinion in Critical Care, 2015, 21, 402-411.	3.2	71
57	Treatment of ventilator-associated pneumonia and ventilator-associated tracheobronchitis in the intensive care unit. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1453-1462.	1.1	2

#	Article	IF	Citations
58	On the antibacterial effects of manuka honey: mechanistic insights. Research and Reports in Biology, 0, , 215.	0.2	12
59	Optimising the administration of antibiotics in critically ill patients. South African Medical Journal, 2015, 105, 419.	0.6	5
60	Aminoglycosides. , 2015, , 310-321.e7.		9
61	Editorial Commentary: Critically Ill Patients WithClostridium difficileInfection: Are 2 Antibiotics Better Than One?. Clinical Infectious Diseases, 2015, 61, 942-944.	5.8	1
62	Activities of Antibiotic Combinations against Resistant Strains of Pseudomonas aeruginosa in a Model of Infected THP-1 Monocytes. Antimicrobial Agents and Chemotherapy, 2015, 59, 258-268.	3.2	17
63	The prevention, diagnosis and management of central venous line infections in children. Journal of Infection, 2015, 71, S59-S75.	3.3	58
64	Medical treatment of prosthetic vascular graft infections: Review of the literature and proposals of a Working Group. International Journal of Antimicrobial Agents, 2015, 46, 254-265.	2.5	76
65	Clinical management of resistance evolution in a bacterial infection. Evolution, Medicine and Public Health, 2015, 2015, 281-288.	2.5	26
66	Global dissemination of extensively drugâ€resistant carbapenemaseâ€producing <scp>E</scp>nterobacteriaceae: clinical perspectives on detection, treatment and infection control. Journal of Internal Medicine, 2015, 277, 501-512.	6.0	254
67	Risk factors and outcome of infections with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in kidney transplant recipients. Infection, 2015, 43, 315-323.	4.7	60
68	When 1 + 1 > 2: Nanostructured composites for hard tissue engineering applications. Materials Science and Engineering C, 2015, 57, 434-451.	7.3	39
69	Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Current Opinion in Pharmacology, 2015, 24, 30-37.	3.5	39
70	In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 5834-5837.	3.2	17
71	Biologically synthesized silver nanoparticles enhances antibiotic activity against Gram-negative bacteria. Journal of Industrial and Engineering Chemistry, 2015, 29, 217-226.	5.8	72
72	Antibiotic Body Burden of Chinese School Children: A Multisite Biomonitoring-based Study. Environmental Science & Technology, 2015, 49, 5070-5079.	10.0	111
73	In Vitro Fractional Inhibitory Concentration (FIC) Study of Cefixime and Azithromycin Fixed Dose Combination (FDC) Against Respiratory Clinical Isolates. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, DC13-5.	0.8	4
74	Is combination therapy for carbapenem-resistantKlebsiella pneumoniaethe new standard of care?. Expert Review of Anti-Infective Therapy, 2015, 13, 1-3.	4.4	6
75	Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia. Future Microbiology, 2015, 10, 357-365.	2.0	18

#	Article	IF	Citations
76	Sensitization of Gram-negative bacteria to rifampin and OAK combinations. Scientific Reports, 2015, 5, 9216.	3.3	49
77	The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria. Clinical Microbiology Reviews, 2015, 28, 337-418.	13.6	1,097
78	Infectious diseases approach to immunocompromised patients in the pediatric intensive care unit. Journal of Pediatric Intensive Care, 2015, 03, 305-313.	0.8	1
79	Mechanisms of antimicrobial resistance in Gram-negative bacilli. Annals of Intensive Care, 2015, 5, 61.	4.6	309
80	Total Synthesis of Albicidin: A Lead Structure from Xanthomonas albilineans for Potent Antibacterial Gyrase Inhibitors. Angewandte Chemie - International Edition, 2015, 54, 1969-1973.	13.8	55
81	Target-Based Resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a Novel Bacterial Type II Topoisomerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2015, 59, 331-337.	3.2	21
82	Pathogenicity phenomena in three model systems: from network mining to emerging system-level properties. Briefings in Bioinformatics, 2015, 16, 169-182.	6.5	1
83	In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates. Annals of Laboratory Medicine, 2016, 36, 138-144.	2.5	14
84	Multidrug-resistant Gram-negative bacteria-resistant infections: epidemiology, clinical issues and therapeutic options. Italian Journal of Medicine, 2016, 10, 364.	0.3	15
85	Enhancement of Antibiotic Efficacy against Multi-drug Resistant Pseudomonas Aeruginosa Infections via Combination with Curcumin and 1-(1-Naphthylmethyl)-Piperazine. Journal of Antimicrobial Agents, 2016, 2, .	0.2	4
86	Novel Microdilution Method to Assess Double and Triple Antibiotic Combination TherapyIn Vitro. International Journal of Microbiology, 2016, 2016, 1-10.	2.3	9
87	In vitro and in vivo antimicrobial activity of combined therapy of silver nanoparticles and visible blue light against Pseudomonas aeruginosa. International Journal of Nanomedicine, 2016, 11, 1749.	6.7	41
88	Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives. Frontiers in Microbiology, 2016, 7, 1789.	3.5	172
89	Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant Enterobacter cloacae. Frontiers in Microbiology, 2016, 7, 2054.	3.5	43
90	Potential strategies for the eradication of multidrug-resistant Gram-negative bacterial infections. Future Microbiology, 2016, 11, 955-972.	2.0	19
91	Solid organ transplant patients: are there opportunities for antimicrobial stewardship?. Clinical Transplantation, 2016, 30, 659-668.	1.6	45
92	Multidrugâ€resistant organisms in liver transplant: Mitigating risk and managing infections. Liver Transplantation, 2016, 22, 1143-1153.	2.4	38
93	Triple-targeting Gram-negative selective antimicrobial peptides capable of disrupting the cell membrane and lipid A biosynthesis. RSC Advances, 2016, 6, 65418-65421.	3.6	8

#	Article	IF	Citations
94	Analysis of the third- and fourth-generation cephalosporin use for the treatment of infections caused by Gram-negative bacteria in hospital settings. International Journal of Clinical Practice, 2016, 70, 1033-1040.	1.7	1
95	Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 3480-3488.	3.2	99
96	Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discovery Today, 2016, 21, 225-238.	6.4	162
97	Antimicrobial therapy in patients with septic shock. Presse Medicale, 2016, 45, e111-e117.	1.9	2
98	Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System. Antimicrobial Agents and Chemotherapy, 2016, 60, 3509-3518.	3.2	17
99	Antibiofilm Peptides: Potential as Broad-Spectrum Agents. Journal of Bacteriology, 2016, 198, 2572-2578.	2.2	163
100	A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles â€“ Nigella sativa oil combinations. Experimental Parasitology, 2016, 166, 150-163.	1.2	44
101	Hybrid antibiotics â€“ clinical progress and novel designs. Expert Opinion on Drug Discovery, 2016, 11, 665-680.	5.0	39
102	Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2016, 60, 4290-4296.	3.2	39
103	5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5539-5544.	2.2	5
104	A nanotechnology based new approach for Trypanosoma evansi chemotherapy: InÂvitro and vivo trypanocidal effect of (-)-Î±-bisabolol. Experimental Parasitology, 2016, 170, 156-160.	1.2	9
105	Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy. International Journal of Antimicrobial Agents, 2016, 48, 239-246.	2.5	51
106	In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates. Diagnostic Microbiology and Infectious Disease, 2016, 86, 184-189.	1.8	27
107	Successful Treatment of Bloodstream Infection Due to Metallo-Î²-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient. Antimicrobial Agents and Chemotherapy, 2016, 60, 5130-5134.	3.2	61
108	In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. BMC Infectious Diseases, 2016, 16, 444.	2.9	12
109	A Drugâ€“Drug Salt Hydrate of Norfloxacin and Sulfathiazole: Enhancement of in Vitro Biological Properties via Improved Physicochemical Properties. Molecular Pharmaceutics, 2016, 13, 3590-3594.	4.6	86
110	New antibiotics from Natureâ€™s chemical inventory. Bioorganic and Medicinal Chemistry, 2016, 24, 6227-6252.	3.0	62
111	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 2016, 63, e61-e111.	5.8	2,405

#	Article	IF	Citations
112	Synthesis of Albicidin Derivatives: Assessing the Role of Nâ€terminal Acylation on the Antibacterial Activity. ChemMedChem, 2016, 11, 1899-1903.	3.2	22
114	Synergistic combinations of polymyxins. International Journal of Antimicrobial Agents, 2016, 48, 607-613.	2.5	71
115	The role of doxycycline in the therapy of multidrug-resistant E. coli â€“ an in vitro study. Scientific Reports, 2016, 6, 31964.	3.3	26
116	Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producingKlebsiella pneumoniaein 24 hin vitrotimeâ€“kill experiments. Journal of Antimicrobial Chemotherapy, 2016, 71, 2321-2325.	3.0	29
117	Aminoglycosides: An Overview. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a027029.	6.2	590
118	Genetically Engineered Phages: a Review of Advances over the Last Decade. Microbiology and Molecular Biology Reviews, 2016, 80, 523-543.	6.6	310
119	Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects. AAPS PharmSciTech, 2016, 17, 1192-1203.	3.3	13
120	Antibacterial effects of electrospun chitosan/poly(ethylene oxide) nanofibrous membranes loaded with chlorhexidine and silver. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1357-1364.	3.3	47
121	Rewiring Gram-Negative Bacteria Cell Surfaces with Bio-Orthogonal Chemistry via Liposome Fusion. Bioconjugate Chemistry, 2016, 27, 1082-1089.	3.6	14
122	Antibiotic cross-resistance in the lab and resistance co-occurrence in the clinic: Discrepancies and implications in E. coli. Infection, Genetics and Evolution, 2016, 40, 155-161.	2.3	22
123	Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance, 2016, 22, 412-431.	2.0	197
124	Pneumopatie nosocomiali acquisite sotto ventilazione meccanica. EMC - Anestesia-Rianimazione, 2016, 21, 1-15.	0.1	0
125	Clove bud oil reduces kynurenine and inhibits pqs A gene expression in P. aeruginosa. Applied Microbiology and Biotechnology, 2016, 100, 3681-3692.	3.6	19
126	The use and risks of antibiotics in critically ill patients. Expert Opinion on Drug Safety, 2016, 15, 667-678.	2.4	25
128	Antimicrobial resistance and synergy in herbal medicine. Journal of Herbal Medicine, 2016, 6, 53-58.	2.0	37
129	Multidrug evolutionary strategies to reverse antibiotic resistance. Science, 2016, 351, aad3292.	12.6	517
130	Combination Effects of Antimicrobial Peptides. Antimicrobial Agents and Chemotherapy, 2016, 60, 1717-1724.	3.2	190
131	Using adjuvants and environmental factors to modulate the activity of antimicrobial peptides. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 926-935.	2.6	54

#	Article	IF	Citations
132	A review of patents (2011â€“2015) towards combating resistance to and toxicity of aminoglycosides. MedChemComm, 2016, 7, 50-68.	3.4	47
133	Adjuvant effect of cranberry proanthocyanidin active fraction on antivirulent property of ciprofloxacin against Pseudomonas aeruginosa. Microbial Pathogenesis, 2016, 90, 98-103.	2.9	23
134	Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2016, 47, 48-55.	2.5	75
135	Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	91
136	Assessment of early combination effects of colistin and meropenem againstPseudomonas aeruginosaandAcinetobacter baumanniiin dynamic time-kill experiments. Infectious Diseases, 2017, 49, 521-527.	2.8	17
137	Phage engineering: how advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. Quantitative Biology, 2017, 5, 42-54.	0.5	27
138	Silver-Decorated Polymeric Micelles Combined with Curcumin for Enhanced Antibacterial Activity. ACS Applied Materials & Interfaces, 2017, 9, 16880-16889.	8.0	126
139	White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs. Journal of Infectious Diseases, 2017, 216, 228-236.	4.0	83
140	Effect of tacticity-derived topological constraints in bactericidal peptides. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1388-1395.	2.6	30
141	Interactions of the antimicrobial peptide nisin Z with conventional antibiotics and the use of nanostructured lipid carriers to enhance antimicrobial activity. International Journal of Pharmaceutics, 2017, 526, 244-253.	5.2	69
142	Antibiotic therapy in the critically ill - expert opinion of the Intensive Care Medicine Scientific Subcommittee of the European Society of Anaesthesiology. European Journal of Anaesthesiology, 2017, 34, 215-220.	1.7	8
143	Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis â€“ A systematic review with meta-analysis and trial sequential analysis. Journal of Infection, 2017, 74, 331-344.	3.3	37
144	Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
145	Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 326-345.	2.1	41
146	Eucalyptus spp. outer bark extracts inhibit Helicobacter pylori growth: in vitro studies. Industrial Crops and Products, 2017, 105, 207-214.	5.2	13
147	The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach?. ACS Infectious Diseases, 2017, 3, 559-563.	3.8	166
148	The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by Î²-Lactams. Clinical Infectious Diseases, 2017, 64, 1582-1588.	5.8	76
149	Proteomic profile of susceptible and multidrug-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae using label-free and immunoproteomic strategies. Research in Microbiology, 2017, 168, 222-233.	2.1	8

#	Article	IF	Citations
150	Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clinical Microbiology Reviews, 2017, 30, 409-447.	13.6	773
151	Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance. Expert Review of Clinical Pharmacology, 2017, 10, 1203-1214.	3.1	42
152	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2017, 96, 1775-1792.	1.8	129
153	Diabetic foot infection: Antibiotic therapy and good practice recommendations. International Journal of Clinical Practice, 2017, 71, e13006.	1.7	58
154	The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?. Expert Review of Anti-Infective Therapy, 2017, 15, 947-954.	4.4	5
155	IMPâ€6 Carbapenemaseâ€Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacinâ€Meropenem in Two Patients. Pharmacotherapy, 2017, 37, e96-e102.	2.6	3
156	Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert Review of Anti-Infective Therapy, 2017, 15, 861-871.	4.4	51
157	Combined Application of Bacterial Predation and Violacein to Kill Polymicrobial Pathogenic Communities. Scientific Reports, 2017, 7, 14415.	3.3	43
158	In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents. Journal of Global Antimicrobial Resistance, 2017, 10, 326-329.	2.2	9
159	Bifunctional antimicrobial conjugates and hybrid antimicrobials. Natural Product Reports, 2017, 34, 832-885.	10.3	140
160	Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	141
161	Suspicion of respiratory tract infection with multidrug-resistant Enterobacteriaceae: epidemiology and risk factors from a Paediatric Intensive Care Unit. BMC Infectious Diseases, 2017, 17, 163.	2.9	10
162	Case 4: A Preterm Infant with a Necrotic Ulcer Over the Perianal Area. NeoReviews, 2017, 18, e448-e452.	0.8	0
163	Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics. Journal of Microbiological Methods, 2017, 132, 69-75.	1.6	11
164	Aminoglycosides. , 2017, , 1233-1238.e1.		6
165	Anticandidal synergistic activity of green tea catechins, antimycotics and copper sulphate as a mean of combinational drug therapy against candidiasis. Journal De Mycologie Medicale, 2017, 27, 33-45.	1.5	17
166	Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Review of Anti-Infective Therapy, 2017, 15, 55-65.	4.4	64
167	Appropriate Antibiotic Therapy. Emergency Medicine Clinics of North America, 2017, 35, 25-42.	1.2	33

#	Article	IF	Citations
168	Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2017, 72, 29-39.	3.0	136
169	Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections. FEMS Microbiology Letters, 2017, 364, .	1.8	8
170	Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. Journal of Antimicrobial Chemotherapy, 2017, 72, 3471-3480.	3.0	84
171	Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries. Frontiers in Pharmacology, 2017, 8, 546.	3.5	64
172	Additivity vs Synergism: Investigation of the Additive Interaction of Cinnamon Bark Oil and Meropenem in Combinatory Therapy. Molecules, 2017, 22, 1733.	3.8	47
173	Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules, 2017, 22, 2267.	3.8	156
174	The Transient Multidrug Resistance Phenotype of Salmonella enterica Swarming Cells Is Abolished by Sub-inhibitory Concentrations of Antimicrobial Compounds. Frontiers in Microbiology, 2017, 8, 1360.	3.5	28
175	Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models. Frontiers in Microbiology, 2017, 8, 2585.	3.5	9
176	A Pseudomonas aeruginosa Quorum-Sensing autoinducer analog enhances the activity of antibiotics against resistant strains. Journal of Medical Investigation, 2017, 64, 101-109.	0.5	1
177	Intensive care unit-acquired Acinetobacter baumannii infections in a Moroccan teaching hospital: epidemiology, risk factors and outcome. Germs, 2017, 7, 193-205.	1.3	23
178	Biofilm inhibitory efficiency of phytol in combination with cefotaxime against nosocomial pathogen Acinetobacter baumannii. Journal of Applied Microbiology, 2018, 125, 56-71.	3.1	19
179	Mitigating the Impact of Antibacterial Drug Resistance through Host-Directed Therapies: Current Progress, Outlook, and Challenges. MBio, 2018, 9, .	4.1	59
180	Sepsis and Infection. , 2018, , 455-468.		1
181	A surfactant polymer dressing potentiates antimicrobial efficacy in biofilm disruption. Scientific Reports, 2018, 8, 873.	3.3	39
182	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Expert Opinion on Pharmacotherapy, 2018, 19, 397-408.	1.8	24
183	Automated time-lapse microscopy a novel method for screening of antibiotic combination effects against multidrug-resistant Gram-negative bacteria. Clinical Microbiology and Infection, 2018, 24, 778.e7-778.e14.	6.0	10
184	Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. Clinical Microbiology and Infection, 2018, 24, 882-888.	6.0	23
185	Semi-mechanistic pharmacokineticâ€“pharmacodynamic modelling of antibiotic drug combinations. Clinical Microbiology and Infection, 2018, 24, 697-706.	6.0	35

#	Article	IF	Citations
186	Assessment and modelling of antibacterial combination regimens. Clinical Microbiology and Infection, 2018, 24, 689-696.	6.0	20
187	2-(2-Nitrovinyl) furan exacerbates oxidative stress response of Escherichia coli to bacteriostatic and bactericidal antibiotics. Microbial Pathogenesis, 2018, 116, 130-134.	2.9	8
188	The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models. European Journal of Pharmaceutical Sciences, 2018, 115, 132-143.	4.0	10
189	Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward â€˜molecularly targetedâ€™ therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 89-110.	4.4	58
190	DeepSynergy: predicting anti-cancer drug synergy with Deep Learning. Bioinformatics, 2018, 34, 1538-1546.	4.1	341
191	Antibiotic Treatment â€“ What Can Be Learned from Point of Injury Experience?. Military Medicine, 2018, 183, 466-471.	0.8	3
192	Beta-Lactam Antibiotics. , 2018, , 1-56.		1
193	Antibacterial naphthoquinone derivatives targeting resistant strain Gram-negative bacteria in biofilms. Microbial Pathogenesis, 2018, 118, 105-114.	2.9	35
194	Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?. Clinical Microbiology Reviews, 2018, 31, .	13.6	218
195	Empiric antibiotic protocols for cancer patients with neutropenia: a singleâ€“center study of treatment efficacy and mortality in patients with bacteremia. International Journal of Antimicrobial Agents, 2018, 51, 71-76.	2.5	4
196	Post-surgical Gangrene with Pseudomonas luteola Resulting in Limb Amputation: A Case Review. Cureus, 2018, 10, e3441.	0.5	3
197	Multidrug resistant bacteria in critically ill patients: a step further antibiotic therapy. Journal of Emergency and Critical Care Medicine, 0, 2, 103-103.	0.7	32
198	In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China. Journal of Thoracic Disease, 2018, 10, 1370-1376.	1.4	10
199	Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation. EcoSal Plus, 2018, 8, .	5.4	75
200	Is synergy the key to treating high-density infections?. Future Microbiology, 2018, 13, 1629-1632.	2.0	12
201	Inhibition of Salmonella Typhimurium adhesion, invasion, and intracellular survival via treatment with methyl gallate alone and in combination with marbofloxacin. Veterinary Research, 2018, 49, 101.	3.0	44
202	Human Antimicrobial Peptide Isolated From Triatoma infestans Haemolymph, Trypanosoma cruzi-Transmitting Vector. Frontiers in Cellular and Infection Microbiology, 2018, 8, 354.	3.9	18
203	Antimicrobial stewardship for acute-care hospitals: An Asian perspective. Infection Control and Hospital Epidemiology, 2018, 39, 1237-1245.	1.8	31

#	Article	IF	Citations
204	Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections. PLoS ONE, 2018, 13, e0203295.	2.5	29
205	Multiple Low Frequency Ultrasound Enhances Bactericidal Activity of Vancomycin against Methicillin-ResistantStaphylococcus aureusBiofilms. BioMed Research International, 2018, 2018, 1-7.	1.9	10
206	Elucidating the survival and response of carbapenem resistant Klebsiella pneumoniae after exposure to imipenem at sub-lethal concentrations. Pathogens and Global Health, 2018, 112, 378-386.	2.3	11
207	An ecosystem framework for understanding and treating disease. Evolution, Medicine and Public Health, 2018, 2018, 270-286.	2.5	11
208	Halogenated trimethoprim derivatives as multidrug-resistant Staphylococcus aureus therapeutics. Bioorganic and Medicinal Chemistry, 2018, 26, 5343-5348.	3.0	5
209	Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens. PLoS Pathogens, 2018, 14, e1007084.	4.7	160
210	Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. Journal of Pharmaceutical Analysis, 2018, 8, 407-412.	5.3	6
211	Antibacterial Efficacy of Polysaccharide Capped Silver Nanoparticles Is Not Compromised by AcrAB-TolC Efflux Pump. Frontiers in Microbiology, 2018, 9, 823.	3.5	25
212	Management of ventilator-associated pneumonia: Need for a personalized approach. Expert Review of Anti-Infective Therapy, 2018, 16, 641-653.	4.4	10
213	In Vitro Antibacterial Interaction of Doripenem and Amikacin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates. Canadian Journal of Infectious Diseases and Medical Microbiology, 2018, 2018, 1-6.	1.9	6
214	Supramolecular Kandinsky circles with high antibacterial activity. Nature Communications, 2018, 9, 1815.	12.8	88
215	Synergistic combination of two antimicrobial agents closing each otherâ€™s mutant selection windows to prevent antimicrobial resistance. Scientific Reports, 2018, 8, 7237.	3.3	89
216	Lantana camara enhances antibacterial potency of antibiotics and exerts synergistic inhibitory effect against pathogenic bacterial species. Oriental Pharmacy and Experimental Medicine, 2018, 18, 381-389.	1.2	2
217	The emergence, maintenance, and demise of diversity in a spatially variable antibiotic regime. Evolution Letters, 2018, 2, 134-143.	3.3	11
218	Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model. PLoS Biology, 2018, 16, e2004356.	5.6	72
219	Comparison of Mismatch Amplification Mutation Assay PCR and PCR-Restriction Fragment Length Polymorphism for Detection of Major Mutations ingyrAandparCofEscherichia coliAssociated with Fluoroquinolone Resistance. Microbial Drug Resistance, 2019, 25, 23-31.	2.0	6
220	Chemical Induction of Aminoglycoside Uptake Overcomes Antibiotic Tolerance and Resistance in Staphylococcus aureus. Cell Chemical Biology, 2019, 26, 1355-1364.e4.	5.2	71
221	Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012â€“2016. Journal of Global Antimicrobial Resistance, 2019, 19, 106-115.	2.2	10

#	Article	IF	Citations
222	Nitrogen-Doped Carbon Quantum Dots for Preventing Biofilm Formation and Eradicating Drug-Resistant Bacteria Infection. ACS Biomaterials Science and Engineering, 2019, 5, 4739-4749.	5.2	58
223	Dual Inhibition of Klebsiella pneumoniae and Pseudomonas aeruginosa Iron Metabolism Using Gallium Porphyrin and Gallium Nitrate. ACS Infectious Diseases, 2019, 5, 1559-1569.	3.8	50
224	In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
225	Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis. Scientific Reports, 2019, 9, 15290.	3.3	88
226	A Practical Approach to Clinical Antibiotic Stewardship in the ICU Patient with Severe Infection. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 435-446.	2.1	13
227	Common Host Responses in Murine Aerosol Models of Infection Caused by Highly Virulent Gram-Negative Bacteria from the Genera Burkholderia, Francisella and Yersinia. Pathogens, 2019, 8, 159.	2.8	5
228	Amphiphilic Triazine Polymer Derivatives as Antibacterial And Anti-atopic Agents in Mice Model. Scientific Reports, 2019, 9, 15161.	3.3	14
229	Improving therapy of severe infections through drug repurposing of synergistic combinations. Current Opinion in Pharmacology, 2019, 48, 92-98.	3.5	51
230	Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate Î²-lactam antibiotics against multidrug-resistant P. aeruginosa. Journal of Antibiotics, 2019, 72, 816-826.	2.0	15
231	Multidrugâ€resistant Acinetobacter baumannii strains with NDMâ€1: Molecular characterization and in vitro efficacy of meropenemâ€based combinations. Experimental and Therapeutic Medicine, 2019, 18, 2924-2932.	1.8	8
232	Gram-negative synergy and mechanism of action of alkynyl bisbenzimidazoles. Scientific Reports, 2019, 9, 14171.	3.3	7
233	Microfluidic-based observation of local bacterial density under antimicrobial concentration gradient for rapid antibiotic susceptibility testing. Biomicrofluidics, 2019, 13, 014108.	2.4	25
234	Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides InÂVitro and in mdx Mice. Molecular Therapy - Nucleic Acids, 2019, 16, 663-674.	5.1	8
235	Competing evolutionary paths in growing populations with applications to multidrug resistance. PLoS Computational Biology, 2019, 15, e1006866.	3.2	13
236	Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. Nature Microbiology, 2019, 4, 1627-1635.	13.3	102
237	Respiratory Membrane Protein Complexes Convert Chemical Energy. Sub-Cellular Biochemistry, 2019, 92, 301-335.	2.4	5
238	CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties . International Journal of Nanomedicine, 2019, Volume 14, 3819-3830.	6.7	76
239	Dual Î²-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition. Scientific Reports, 2019, 9, 9098.	3.3	16

#	Article	IF	Citations
240	Antimicrobial Stewardship in Patients with Hematological Malignancies: Key Considerations. Current Treatment Options in Infectious Diseases, 2019, 11, 161-176.	1.9	4
241	Development of de novo resistance in Salmonella Typhimurium treated with antibiotic combinations. FEMS Microbiology Letters, 2019, 366, .	1.8	4
242	Multidrugâ€resistant Gramâ€negative bacterial infections in solid organ transplant recipientsâ€"Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13594.	1.6	87
243	Five rules for resistance management in the antibiotic apocalypse, a road map for integrated microbial management. Evolutionary Applications, 2019, 12, 1079-1091.	3.1	74
244	Heterodimeric Rifampicinâ€"Tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol inÂvitro and in a Galleria mellonella inÂvivo model. European Journal of Medicinal Chemistry, 2019, 174, 16-32.	5.5	27
245	Comparable Efficacy and Better Safety of Double Î²-Lactam Combination Therapy versus Î²â€Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
246	Evolutionary ecology meets the antibiotic crisis. Evolution, Medicine and Public Health, 2019, 2019, 37-45.	2.5	43
247	Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
248	Combinational effect of curcumin and metformin against gentamicinâ€induced nephrotoxicity: Involvement of antioxidative, antiâ€inflammatory and antiapoptotic pathway. Journal of Food Biochemistry, 2019, 43, e12836.	2.9	32
249	A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	28
250	Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs. Progress in Molecular Biology and Translational Science, 2019, 163, 487-522.	1.7	19
251	Synergy between Synthetic Antimicrobial Polymer and Antibiotics: A Promising Platform To Combat Multidrug-Resistant Bacteria. ACS Infectious Diseases, 2019, 5, 1357-1365.	3.8	59
252	Drugs for the Prevention and Treatment of Sepsis in the Newborn. Clinics in Perinatology, 2019, 46, 327-347.	2.1	14
253	On-chip phenotypic investigation of combinatory antibiotic effects by generating orthogonal concentration gradients. Lab on A Chip, 2019, 19, 959-973.	6.0	27
254	WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain. Oman Medical Journal, 2019, 34, 184-193.	1.0	198
255	Antibiotic sensitivity of bacteria isolated from the oral cavities of live white sharks (Carcharodon) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	0
256	Clonal Confinement of a Highly Mobile Resistance Element Driven by Combination Therapy in Rhodococcus equi. MBio, 2019, 10, .	4.1	22
257	Bacterial Biofilm Eradication Agents: A Current Review. Frontiers in Chemistry, 2019, 7, 824.	3.6	338

#	Article	IF	Citations
258	Antibiotic regimens for neonatal sepsis - a protocol for a systematic review with meta-analysis. Systematic Reviews, 2019, 8, 306.	5.3	19
259	When One Drug Is Not Enough. Clinics in Laboratory Medicine, 2019, 39, 345-358.	1.4	19
260	Variability in the Adaptive Response of Antibiotic-ResistantSalmonellaTyphimurium to Environmental Stresses. Microbial Drug Resistance, 2019, 25, 182-192.	2.0	15
261	Repurposing azithromycin and rifampicin against Gram-negative pathogens by combination with peptide potentiators. International Journal of Antimicrobial Agents, 2019, 53, 868-872.	2.5	18
262	Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections. Antiviral Research, 2019, 161, 116-124.	4.1	29
263	Plantaricins markedly enhance the effects of traditional antibiotics againstStaphylococcus epidermidis. Future Microbiology, 2019, 14, 195-205.	2.0	13
264	Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Medicine, 2019, 45, 172-189.	8.2	155
265	Antibacterial Carbonâ€Based Nanomaterials. Advanced Materials, 2019, 31, e1804838.	21.0	452
266	Combination drug therapy via nanocarriers against infectious diseases. European Journal of Pharmaceutical Sciences, 2019, 127, 121-141.	4.0	62
267	Prevalence of Î²-haemolytic multi-drug resistant E. coli in cow and camel milk in Kenya. Journal Fur Verbraucherschutz Und Lebensmittelsicherheit, 2019, 14, 55-61.	1.4	1
268	Polydopamine â€“aminoglycoside nanoconjugates: Synthesis, characterization, antimicrobial evaluation and cytocompatibility. Materials Science and Engineering C, 2020, 107, 110284.	7.3	17
269	Estimating the association between antibiotic exposure and colonization with extended-spectrum Î²-lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study. Clinical Microbiology and Infection, 2020, 26, 87-94.	6.0	34
271	Advances in the therapy of bacterial bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 158-167.	6.0	33
272	A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. International Journal of Antimicrobial Agents, 2020, 55, 105833.	2.5	81
273	Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. International Journal of Pharmaceutics, 2020, 575, 118915.	5.2	43
274	Poly (Glycerol Adipate): From a Functionalized Nanocarrier to a Polymeric-Prodrug Matrix to Create Amorphous Solid Dispersions. Journal of Pharmaceutical Sciences, 2020, 109, 1347-1355.	3.3	14
275	Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Review of Anti-Infective Therapy, 2020, 18, 5-15.	4.4	101
276	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020, 46, 245-265.	8.2	97

#	Article	IF	Citations
277	In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient. Open Forum Infectious Diseases, 2020, 7, ofz545.	0.9	5
278	Rational design of balanced dual-targeting antibiotics with limited resistance. PLoS Biology, 2020, 18, e3000819.	5.6	20
279	CaCO3 crystals as versatile carriers for controlled delivery of antimicrobials. Journal of Controlled Release, 2020, 328, 470-489.	9.9	62
280	Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains ofKlebsiella pneumoniae. Pathogens and Disease, 2020, 78, .	2.0	5
281	Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data. Lancet Microbe, The, 2020, 1, e154-e164.	7.3	42
282	A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. Advanced Science, 2020, 7, 2001374.	11.2	53
283	Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia. Expert Review of Anti-Infective Therapy, 2020, 18, 1177-1185.	4.4	2
284	3D microfluidic gradient generator for combination antimicrobial susceptibility testing. Microsystems and Nanoengineering, 2020, 6, 92.	7.0	25
285	Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 3170-3184.	3.5	20
286	Current Trends in Experimental and Computational Approaches to Combat Antimicrobial Resistance. Frontiers in Genetics, 2020, 11, 563975.	2.3	12
287	The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design. Frontiers in Microbiology, 2020, 11, 1669.	3.5	163
288	Approach to the Treatment of Patients with Serious Multidrugâ€Resistant Pseudomonas aeruginosa Infections. Pharmacotherapy, 2020, 40, 952-969.	2.6	26
289	In Vitro Evaluation of Antimicrobial Peptide Tridecaptin M in Combination with Other Antibiotics against Multidrug Resistant Acinetobacter baumannii. Molecules, 2020, 25, 3255.	3.8	14
290	In vitro Activity of Robenidine Analog NCL195 in Combination With Outer Membrane Permeabilizers Against Gram-Negative Bacterial Pathogens and Impact on Systemic Gram-Positive Bacterial Infection in Mice. Frontiers in Microbiology, 2020, 11, 1556.	3.5	14
291	Management of E.Âcoliï»¿ Sepsis. , 2020, , .		2
292	Combination of guanidinium and quaternary ammonium polymers with distinctive antimicrobial mechanisms achieving a synergistic antimicrobial effect. Biomaterials Science, 2020, 8, 6920-6929.	5.4	21
293	Silver-decorated, light-activatable polymeric antimicrobials for combined chemo-photodynamic therapy of drug-resistant bacterial infection. Biomaterials Science, 2020, 8, 6350-6361.	5.4	20
294	Acinetobacter baumannii Sequence Types Harboring Genes Encoding Aminoglycoside Modifying Enzymes and 16SrRNA Methylase; a Multicenter Study from Pakistan . Infection and Drug Resistance, 2020, Volume 13, 2855-2862.	2.7	15

#	Article	IF	Citations
295	Isothermal microcalorimetric determination of the inhibition of Candida species by antifungals. Thermochimica Acta, 2020, 694, 178806.	2.7	1
296	Assessment of cross-resistance potential to serial antibiotic treatments in antibiotic-resistant Salmonella Typhimurium. Microbial Pathogenesis, 2020, 148, 104478.	2.9	8
297	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
298	A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance. Cell, 2020, 181, 1518-1532.e14.	28.9	202
299	Serum bactericidal titres for monitoring antimicrobial therapy: current status and potential role in the management of multidrug-resistant Gram-negative infections. Clinical Microbiology and Infection, 2020, 26, 1338-1344.	6.0	8
300	Expect the Unexpected: A Rare Case of Pseudomonas aeruginosa Endocarditis. IDCases, 2020, 21, e00787.	0.9	5
301	Combination therapy: Current status and future perspectives. , 2020, , 1-38.		0
302	A mechanistic approach to prove the efficacy of combination therapy against New Delhi metallo-Î²-lactamases producing bacterial strain: a molecular and biochemical approach. European Journal of Medical Research, 2020, 25, 19.	2.2	2
303	New approaches for targeting drug resistance through drug combination. , 2020, , 221-246.		1
304	Plantaricin NC8 Î±Î² exerts potent antimicrobial activity against Staphylococcus spp. and enhances the effects of antibiotics. Scientific Reports, 2020, 10, 3580.	3.3	20
305	Synergistic antimicrobial effects of photodynamic antimicrobial chemotherapy and gentamicin on Staphylococcus aureus and multidrug-resistant Staphylococcus aureus. Photodiagnosis and Photodynamic Therapy, 2020, 30, 101703.	2.6	11
306	Multitarget Approaches against Multiresistant Superbugs. ACS Infectious Diseases, 2020, 6, 1346-1365.	3.8	103
307	Suppression of antibiotic resistance evolution by single-gene deletion. Scientific Reports, 2020, 10, 4178.	3.3	15
308	Antibiogram and beta-lactamase genes among cefotaxime resistant E. coli from wastewater treatment plant. Antimicrobial Resistance and Infection Control, 2020, 9, 46.	4.1	29
309	Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?. Journal of Clinical Medicine, 2020, 9, 514.	2.4	27
310	Combined Efficacy of an Antimicrobial Cationic Peptide Polymer with Conventional Antibiotics to Combat Multidrug-Resistant Pathogens. ACS Infectious Diseases, 2020, 6, 1228-1237.	3.8	41
311	Preliminary Investigation of the Antibacterial Activity of Antitumor Drug 3-Amino-1,2,4-Benzotriazine-1,4-Dioxide (Tirapazamine) and its Derivatives. Applied Sciences (Switzerland), 2020, 10, 4062.	2.5	3
312	How antibiotics work together: molecular mechanisms behind combination therapy. Current Opinion in Microbiology, 2020, 57, 31-40.	5.1	45

#	Article	IF	Citations
313	Quaternized polymer-based nanostructures confer antimicrobial efficacy against multidrug-resistant bacteria. New Journal of Chemistry, 2020, 44, 3874-3881.	2.8	4
314	Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study. European Journal of Pediatrics, 2020, 179, 1247-1254.	2.7	10
315	Antibiotic burden of school children from Tibetan, Hui, and Han groups in the Qinghaiâ€“Tibetan Plateau. PLoS ONE, 2020, 15, e0229205.	2.5	3
316	New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae. Translational Research, 2020, 220, 14-32.	5.0	13
317	Bloodstream infections in critically ill patients: an expert statement. Intensive Care Medicine, 2020, 46, 266-284.	8.2	159
318	Combinations of early generation antibiotics and antimicrobial peptides are effective against a broad spectrum of bacterial biothreat agents. Microbial Pathogenesis, 2020, 142, 104050.	2.9	20
319	Antibiotic use among hospitalized patients in northern Nigeria: a multicenter point-prevalence survey. BMC Infectious Diseases, 2020, 20, 86.	2.9	61
320	Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	43
321	Honokiol Restores Polymyxin Susceptibility to MCR-1-Positive Pathogens both In Vitro and In Vivo. Applied and Environmental Microbiology, 2020, 86, .	3.1	20
322	Effective Elimination of Contaminant Antibiotics Using High-Surface-Area Magnetic-Functionalized Graphene Nanocomposites Developed from Plastic Waste. Materials, 2020, 13, 1517.	2.9	22
323	Multicenter Evaluation of the BD Phoenix CPO Detect Test for Detection and Classification of Carbapenemase-Producing Organisms in Clinical Isolates. Journal of Clinical Microbiology, 2020, 58, .	3.9	11
324	Functionalized Polymers Enhance Permeability of Antibiotics in Gramâ€Negative MDR Bacteria and Biofilms for Synergistic Antimicrobial Therapy. Advanced Therapeutics, 2020, 3, 2000005.	3.2	20
325	Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention. Advanced Therapeutics, 2020, 3, 2000034.	3.2	44
327	Effectiveness of Antibiotic Combination Treatments to Control Heteroresistant Salmonella Typhimurium. Microbial Drug Resistance, 2021, 27, 441-449.	2.0	5
328	Rapid antimicrobial susceptibility tests on an integrated microfluidic device for precision medicine of antibiotics. Biosensors and Bioelectronics, 2021, 176, 112890.	10.1	7
329	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2021, 72, e169-e183.	5.8	292
330	The Genomic Basis of Rapid Adaptation to Antibiotic Combination Therapy in Pseudomonas aeruginosa. Molecular Biology and Evolution, 2021, 38, 449-464.	8.9	21
331	Green synthesis of carbon nanoparticles: characterization and their biocidal properties. , 2021, , 277-306.		3

#	Article	IF	Citations
332	Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening. Journal of Antimicrobial Chemotherapy, 2021, 76, 1001-1009.	3.0	22
333	Collateral sensitivity associated with antibiotic resistance plasmids. ELife, 2021, 10, .	6.0	16
334	In-vitro synergistic activity of colistin and meropenem against clinical isolates of carbapenem resistant E.coli and Klebsiella pneumoniae by checkerboard method. Indian Journal of Medical Microbiology, 2021, 39, 6-10.	0.8	4
335	Categorizing microbial growth inhibition through quantification of 16S rRNA growth marker with stripwells covering a spectrum of antimicrobial conditions. MethodsX, 2021, 8, 101453.	1.6	4
336	A quinine-based quaternized polymer: a potent scaffold with bactericidal properties without resistance. Polymer Chemistry, 2021, 12, 2397-2403.	3.9	5
337	Periplanetasin-2 Enhances the Antibacterial Properties of Vancomycin or Chloramphenicol in Escherichia coli. Journal of Microbiology and Biotechnology, 2021, 31, 189-196.	2.1	4
338	Antibiofilm activity of Fmoc-phenylalanine against Gram-positive and Gram-negative bacterial biofilms. Journal of Antibiotics, 2021, 74, 407-416.	2.0	10
339	TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations. PLoS Computational Biology, 2021, 17, e1008653.	3.2	81
340	Recalibrating Our Approach to the Management of Sepsis. How the Four Moments of Antibiotic Decision-Making Can Help. Annals of the American Thoracic Society, 2021, 18, 200-203.	3.2	1
341	Prevalent Synergy and Antagonism Among Antibiotics and Biocides in Pseudomonas aeruginosa. Frontiers in Microbiology, 2020, 11, 615618.	3.5	12
342	Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent ciprofloxacin derivatives. Bioorganic Chemistry, 2021, 108, 104658.	4.1	11
343	Feasibility and potential significance of rapid in vitro qualitative phenotypic antimicrobial susceptibility testing of gram-negative bacilli with the ProMax system. PLoS ONE, 2021, 16, e0249203.	2.5	3
344	Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria. Accounts of Chemical Research, 2021, 54, 1623-1634.	15.6	14
345	Caffeic Acid and Its Derivatives: Antimicrobial Drugs toward Microbial Pathogens. Journal of Agricultural and Food Chemistry, 2021, 69, 2979-3004.	5.2	120
346	Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision. International Journal of Antimicrobial Agents, 2021, 57, 106269.	2.5	8
347	Simultaneous delivery of several antimicrobial drugs from multiâ€compartment glycerolâ€silicone membranes. Journal of Applied Polymer Science, 2021, 138, 50780.	2.6	0
348	Prevalence and antimicrobial susceptibility profile of multidrug-resistant bacteria among intensive care units patients at Ain Shams University Hospitals in Egyptâ€"a retrospective study. Journal of the Egyptian Public Health Association, The, 2021, 96, 7.	2.5	22
349	Cytotoxicity and antimicrobial activity of synthetic peptides alone or in combination with conventional antimicrobials against fish pathogenic bacteria. Journal of Applied Microbiology, 2021, 131, 1762-1774.	3.1	8

#	Article	IF	Citations
350	Co-delivery of ciprofloxacin and colistin using microcontainers for bacterial biofilm treatment. International Journal of Pharmaceutics, 2021, 599, 120420.	5.2	3
351	How to kill Pseudomonasâ€"emerging therapies for a challenging pathogen. Annals of the New York Academy of Sciences, 2021, 1496, 59-81.	3.8	15
352	In vitro Antimicrobial Synergy Testing of Extensively Drug-Resistant Clinical Isolates at an Organ Transplant Center in Nepal. Infection and Drug Resistance, 2021, Volume 14, 1669-1677.	2.7	10
353	Tailored gentamicin release from silica nanocarriers coated with polyelectrolyte multilayers. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 614, 126210.	4.7	8
354	Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. Frontiers in Chemistry, 2021, 9, 659845.	3.6	24
355	Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections. Antibiotics, 2021, 10, 520.	3.7	4
356	Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance. Current Topics in Medicinal Chemistry, 2021, 21, 737-752.	2.1	32
358	Mixed biofilms of pathogenic Candida-bacteria: regulation mechanisms and treatment strategies. Critical Reviews in Microbiology, 2021, 47, 699-727.	6.1	26
359	The effect of EDTA in combination with some antibiotics against clinical isolates of gram negative bacteria in Mansoura, Egypt. Microbial Pathogenesis, 2021, 154, 104840.	2.9	5
360	Physicochemical Features and Peculiarities of Interaction of AMP with the Membrane. Pharmaceuticals, 2021, 14, 471.	3.8	46
361	Antibiotic regimens for late-onset neonatal sepsis. The Cochrane Library, 2021, 2021, CD013836.	2.8	16
362	Antibiotic regimens for early-onset neonatal sepsis. The Cochrane Library, 2021, 2021, CD013837.	2.8	20
363	Synergism of Zinc Oxide Quantum Dots with Antifungal Drugs: Potential Approach for Combination Therapy against Drug Resistant Candida albicans. Frontiers in Nanotechnology, 2021, 3, .	4.8	10
364	A Multicenter Observational Study Evaluating Outcomes Associated With Antibiotic Combination Versus Monotherapy in Patients With Septic Shock. , 2021, 3, e0383.		0
365	Cefiderocol-Based Combination Therapy for â€œDifficult-to-Treatâ€•Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Antibiotics, 2021, 10, 652.	3.7	54
366	Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2021, 56, 3634-3643.	2.0	5
367	The Lambert function should be in the engineering mathematical toolbox. Computers and Chemical Engineering, 2021, 148, 107259.	3.8	10
368	Hidden Fluids in Plain Sight: Identifying Intravenous Medication Classes as Contributors to Intensive Care Unit Fluid Intake. Hospital Pharmacy, 2022, 57, 230-236.	1.0	8

#	Article	IF	Citations
369	The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella Pneumoniae Isolates. Antibiotics, 2021, 10, 736.	3.7	5
370	Blood Stream Infections from MDR Bacteria. Life, 2021, 11, 575.	2.4	10
371	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. Journal of Global Antimicrobial Resistance, 2021, 25, 268-281.	2.2	62
372	Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling. BMC Veterinary Research, 2021, 17, 212.	1.9	7
373	Treatment of patients with serious infections due to carbapenemâ€resistant Acinetobacter baumannii: How viable are the current options?. Pharmacotherapy, 2021, 41, 762-780.	2.6	22
375	Molecular survey of aminoglycoside-resistant Acinetobacter baumannii isolated from tertiary hospitals in Qazvin, Iran. New Microbes and New Infections, 2021, 42, 100883.	1.6	1
376	Carbon quantum dots modified Ag2S/CS nanocomposite as effective antibacterial agents. Journal of Inorganic Biochemistry, 2021, 220, 111456.	3.5	14
377	Association between antimicrobial usage and resistance in Salmonella from poultry farms in Nigeria. BMC Veterinary Research, 2021, 17, 234.	1.9	26
378	Current opinion in management of septic shock due to Gram-negative bacteria. Current Opinion in Infectious Diseases, 2021, 34, 718-727.	3.1	6
379	Detection of NDM-1 and VIM Genes in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Isolates from a Tertiary Health-Care Center in Kathmandu, Nepal. Chemotherapy, 2021, 66, 199-209.	1.6	6
380	Synergistic Antibacterial and Antibiofilm Activity of the MreB Inhibitor A22 Hydrochloride in Combination with Conventional Antibiotics against Pseudomonas aeruginosa and Escherichia coli Clinical Isolates. International Journal of Microbiology, 2021, 2021, 1-17.	2.3	5
381	Plasma-Activated Saline Promotes Antibiotic Treatment of Systemic Methicillin-Resistant Staphylococcus aureus Infection. Antibiotics, 2021, 10, 1018.	3.7	9
382	Antibacterial Activity and Synergetic Mechanism of Carbon Dots against Gram-Positive and -Negative Bacteria. ACS Applied Bio Materials, 2021, 4, 6937-6945.	4.6	51
383	Major pulmonary complications following Hematopoietic stem cell transplantation: What the pulmonologist needs to know. Respiratory Medicine, 2021, 185, 106493.	2.9	6
384	Using response surface models to analyze drug combinations. Drug Discovery Today, 2021, 26, 2014-2024.	6.4	4
385	Review on Surface Treatment for Implant Infection via Gentamicin and Antibiotic Releasing Coatings. Coatings, 2021, 11, 1006.	2.6	14
386	Antibiofilm Activity of Gallium(III) Complexed Anionic Polymers in Combination with Antibiotics. Macromolecular Rapid Communications, 2021, 42, 2100255.	3.9	1
387	Spectrum of Microorganisms, Antibiotic Resistance Pattern, and Treatment Outcomes Among Patients With Empyema Thoracis: A Descriptive Cross-Sectional Study From the Bahawal Victoria Hospital Bahawalpur, Punjab, Pakistan. Frontiers in Medicine, 2021, 8, 665963.	2.6	3

#	Article	IF	Citations
388	Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes. Current Drug Targets, 2021, 22, 1424-1436.	2.1	34
389	Role of medicinal plants from North Western Himalayas as an efflux pump inhibitor against MDR AcrAB-TolC Salmonella enterica serovar typhimurium: In vitro and In silico studies. Journal of Ethnopharmacology, 2022, 282, 114589.	4.1	23
390	The existence and expression of aminoglycoside resistance genes among multidrug-resistant Escherichia coli isolates in intensive care unit centers. Gene Reports, 2021, 25, 101315.	0.8	2
391	Simultaneous in vitro simulation of multiple antimicrobial agents with different elimination half-lives in a pre-clinical infection model. Computers and Chemical Engineering, 2021, 155, 107540.	3.8	4
392	Combination therapy. , 2021, , 1-46.		0
393	Antibiotic regimens for early-onset neonatal sepsis. The Cochrane Library, 0, , .	2.8	1
394	Antibiotic regimens for late-onset neonatal sepsis. The Cochrane Library, 0, , .	2.8	1
395	Assessment of the protective effect of green tea extract against ciprofloxacin-induced chondrotoxicity in albino rats (histochemical, and immunohistochemical study). Archives of Medical Science - Civilization Diseases, 2021, 6, 68-74.	0.1	0
396	Phenotypic microbial response to antimicrobial exposure conditions with a molecular analysis quantification of species-specific 16S rRNA content. MethodsX, 2021, 8, 101468.	1.6	1
397	Synthetic Antimicrobial Polymers in Combination Therapy: Tackling Antibiotic Resistance. ACS Infectious Diseases, 2021, 7, 215-253.	3.8	71
398	Antibacterial Drug Discovery: Perspective Insights. , 2019, , 1-21.		4
399	Combination of Drugs: An Effective Approach for Enhancing the Efficacy of Antibiotics to Combat Drug Resistance. , 2019, , 427-440.		1
400	Nosocomial Pneumonia. , 2015, , 3325-3333.e4.		7
401	Development of mechanism-based antibacterial synergy between Fmoc-phenylalanine hydrogel and aztreonam. Biomaterials Science, 2020, 8, 1996-2006.	5.4	20
402	In vivo activity of co-trimoxazole combined with colistin against Acinetobacter baumannii producing OXA-23 in a Galleria mellonella model. Journal of Medical Microbiology, 2019, 68, 52-59.	1.8	9
405	High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance. PLoS Biology, 2017, 15, e2001644.	5.6	53
406	Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies. PLoS Computational Biology, 2017, 13, e1005745.	3.2	51
407	Methyl-Hydroxylamine as an Efficacious Antibacterial Agent That Targets the Ribonucleotide Reductase Enzyme. PLoS ONE, 2015, 10, e0122049.	2.5	12

#	Article	IF	Citations
408	Rescued chlorhexidine activity by resveratrol against carbapenem-resistant Acinetobacter baumannii via down-regulation of AdeB efflux pump. PLoS ONE, 2020, 15, e0243082.	2.5	22
409	A Combination Antibiogram to Guide Empiric Therapy for Pseudomonas aeruginosa Infections. Year-to-Year Variation and Influence of Day of Hospitalization Isolation. Journal of Clinical and Laboratory Medicine, 2017, 1, .	0.1	2
410	Functional Characterization of a Novel Hybrid Peptide with High Potency against Gram-negative Bacteria. Current Pharmaceutical Design, 2020, 26, 376-385.	1.9	4
412	Novel therapeutic approaches for the management of cystic fibrosis. Multidisciplinary Respiratory Medicine, 2020, 15, 690.	1.5	12
413	Mutant Selection Windows of Azalomycin F_{5a} in Combination with Vitamin K₃ against Methicillin-Resistant <i>Staphylococcus aureus</i>. Journal of Biosciences and Medicines, 2016, 04, 162-174.	0.2	1
414	Mathematical Modelling of Listeriosis Epidemics in Animal and Human Population with Optimal Control.. Tamkang Journal of Mathematics, 2020, 51, 261-287.	0.3	9
415	NDM-1 and rmtC-Producing Klebsiella pneumoniae Isolates in Turkey. Jundishapur Journal of Microbiology, 2016, 9, e33990.	0.5	12
416	A retrospective study to evaluate the efficacy of a new antibiotic adjuvant entity (Î²-lactam/Î²-lactamase) Tj ETQq1 1 0.784314 rgBT /Ov Infectious Diseases, 2015, 3, 3.	0.2	1
417	Biofilms and antibiotic susceptibility of multidrug-resistant bacteria from wild animals. PeerJ, 2018, 6, e4974.	2.0	19
418	Cholesteroled polymer (Chol-<i>b</i>-Lys)-based nanoparticles (CL-NPs) confer antibacterial efficacy without resistance. New Journal of Chemistry, 2021, 45, 20743-20750.	2.8	4
419	Polymyxin B-modified conjugated oligomer nanoparticle for targeted identification and enhanced photodynamic antimicrobial therapy. Chemical Communications, 2021, 57, 11244-11247.	4.1	3
420	Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Advanced Drug Delivery Reviews, 2021, 179, 114004.	13.7	55
421	Multiple lipid nanoparticles as antimicrobial drug delivery systems. Journal of Drug Delivery Science and Technology, 2022, 67, 102887.	3.0	8
422	Bioactive Synthetic Polymers. Advanced Materials, 2022, 34, e2105063.	21.0	66
423	A systematic review from basics to omics on bacteriophage applications in poultry production and processing. Critical Reviews in Food Science and Nutrition, 2023, 63, 3097-3129.	10.3	26
424	Leveraging laboratory and clinical studies to design effective antibiotic combination therapy. Current Opinion in Microbiology, 2021, 64, 68-75.	5.1	7
425	Inhibitory and Bactericidal Potential of Some Indigenous Functional Food-Plants Used in the O.R. Tambo District Municipality of South Africa. Journal of Biosciences and Medicines, 2014, 02, 34-40.	0.2	1
426	Analysis of a fatal left ventricular assist device infection: a case report and discussion. Southwest Journal of Pulmonary & Critical Care, 2014, 10, 16-20.	0.0	0

#	Article	IF	Citations
427	EDTA-Treated Cell Membrane and Multiple Subculturing Affect the Virulence of Enteropathogenic Bacteria. Research Journal of Microbiology, 2015, 10, 158-169.	0.2	1
430	Pharmacodynamic Evaluation: Infectious Diseases. , 2018, , 1-18.		0
431	A Case of Necrotising Soft-tissue Infection and Sepsis Caused by Shewanella haliotis . Journal of the Japanese Association for Infectious Diseases, 2018, 92, 380-385.	0.0	0
432	In Vitro Antimicrobial Combinations for Pan-Drug Resistant Acinetobacter Species. The Egyptian Journal of Hospital Medicine, 2018, 72, 4469-4472.	0.1	0
434	In vitro Evaluation of Antibacterial Potential of Combined Extract from Kalanchoe pinnata and Citrus aurantifolia on Otitis-media Pathogens. Asian Journal of Biological Sciences, 2018, 12, 61-66.	0.2	0
435	Chemical Induction of Aminoglycoside Uptake Overcomes Antibiotic Tolerance and Resistance in Staphylococcus Aureus. SSRN Electronic Journal, 0, , .	0.4	2
436	Utilization of antimicrobial agents in patients on ventilator in medical Intensive Care Unit at a tertiary care teaching hospital: A prospective study. Perspectives in Clinical Research, 2019, 10, 130.	1.0	0
440	OUP accepted manuscript. JAC-Antimicrobial Resistance, 2021, 3, dlab175.	2.1	3
441	Frequency of Ventilator Associated Pneumonias in Patients in the Intensive Care Unit. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2020, 74, 285.	0.9	2
442	Pharmacodynamic Evaluation: Infectious Diseases. , 2020, , 325-342.		0
444	Uncovering Key Metabolic Determinants of the Drug Interactions Between Trimethoprim and Erythromycin in Escherichia coli. Frontiers in Microbiology, 2021, 12, 760017.	3.5	2
445	Evaluation of the Therapeutic Outcomes of Antibiotic Regimen Against Carbapenemase-Producing Klebsiella pneumoniae: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 597907.	3.5	4
446	Combination antibiotic therapy and synergy in HAP and VAP. , 0, , 302-311.		0
447	Advantages of laboratory natural selection in the applied sciences. Journal of Evolutionary Biology, 2022, 35, 5-22.	1.7	3
448	Therapeutic drug monitoring of amikacin: quantification in plasma by liquid chromatography-tandem mass spectrometry and work experience of clinical pharmacists. European Journal of Hospital Pharmacy, 2022, 29, e77-e82.	1.1	6
449	Identification of Multiple Low-Level Resistance Determinants and Coselection of Motility Impairment upon Sub-MIC Ceftriaxone Exposure in Escherichia coli. MSphere, 2021, 6, e0077821.	2.9	7
451	Water-soluble branched polymer for combined chemo-immunotherapy of bacterial infections. Biomaterials Science, 2021, 9, 8347-8355.	5.4	6
452	Combinatorial nanodroplet platform for screening antibiotic combinations. Lab on A Chip, 2022, 22, 621-631.	6.0	12

#	Article	IF	Citations
454	Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 191-218.	2.1	7
455	Biofilm Formation as Valuable Target to Fight against Severe Chronic Infections. Current Medicinal Chemistry, 2022, 29, 4307-4310.	2.4	20
456	Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer Discovery, 2022, 12, 606-624.	9.4	93
457	Silver Mesoporous Silica Nanoparticles: Fabrication to Combination Therapies for Cancer and Infection. Chemical Record, 2022, , e202100287.	5.8	4
458	Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nature Communications, 2022, 13, 302.	12.8	97
459	Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2022, 59, 106517.	2.5	21
460	Dissemination Routes of Carbapenem and Pan-Aminoglycoside Resistance Mechanisms in Hospital and Urban Wastewater Canalizations of Ghana. MSystems, 2022, 7, e0101921.	3.8	7
461	Prevention, inhibition, and degradation effects of melittin alone and in combination with vancomycin and rifampin against strong biofilm producer strains of methicillin-resistant Staphylococcus epidermidis. Biomedicine and Pharmacotherapy, 2022, 147, 112670.	5.6	20
462	Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics, 2022, 11, 200.	3.7	101
463	Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infectious Diseases and Therapy, 2022, 11, 661-682.	4.0	80
464	Potential Synergistic Antibiotic Combinations against Fluoroquinolone-Resistant Pseudomonas aeruginosa. Pharmaceuticals, 2022, 15, 243.	3.8	5
465	Antibiotic Combination Therapy: A Strategy to Overcome Bacterial Resistance to Aminoglycoside Antibiotics. Frontiers in Pharmacology, 2022, 13, 839808.	3.5	33
466	The Antimicrobial Peptide Esc(1-21) Synergizes with Colistin in Inhibiting the Growth and in Killing Multidrug Resistant Acinetobacter baumannii Strains. Antibiotics, 2022, 11, 234.	3.7	9
467	The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings. Antibiotics, 2022, 11, 323.	3.7	10
468	Synergistic antimicrobial activity of <scp>TZP4</scp> with conventional antibiotics against antibioticâ€resistant Pseudomonas aeruginosa. Bulletin of the Korean Chemical Society, 2022, 43, 739-744.	1.9	0
469	Top Myths of Diagnosis and Management of Infectious Diseases in Hospital Medicine. American Journal of Medicine, 2022, 135, 828-835.	1.5	3
470	Overcoming Stenotrophomonas maltophilia Resistance for a More Rational Therapeutic Approach. Open Forum Infectious Diseases, 2022, 9, ofac095.	0.9	16
471	Modulation of gentamicin-induced acute kidney injury by myo-inositol oxygenase via the ROS/ALOX-12/12-HETE/GPR31 signaling pathway. JCI Insight, 2022, 7, .	5.0	14

#	Article	IF	Citations
472	Addressing the Needs of the Rapidly Aging Society through the Development of Multifunctional Bioactive Coatings for Orthopedic Applications. International Journal of Molecular Sciences, 2022, 23, 2786.	4.1	12
473	The physiology and genetics of bacterial responses to antibiotic combinations. Nature Reviews Microbiology, 2022, 20, 478-490.	28.6	54
474	Potential risks of treating bacterial infections with a combination of Î²-lactam and aminoglycoside antibiotics: A systematic quantification of antibiotic interactions in E. coli blood stream infection isolates. EBioMedicine, 2022, 78, 103979.	6.1	8
475	Amphiphilic cyclic peptide [W4KR5]-Antibiotics combinations as broad-spectrum antimicrobial agents. European Journal of Medicinal Chemistry, 2022, 235, 114278.	5.5	7
476	Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis. Antibiotics, 2021, 10, 1483.	3.7	1
478	Investigation of salicylidene acylhydrazides derivatives: Molecular Docking, ADMET, and Molecular Dynamic Simulations were used in conjunction towards the design of new Yersinia pseudotuberculosis inhibitors. Turkish Computational and Theoretical Chemistry, 2022, 6, 9-30.	0.5	3
479	Morphological Characterization of Antibiotic Combinations. ACS Infectious Diseases, 2022, 8, 66-77.	3.8	3
480	Multiple Secondary Healthcare-Associated Infections Due to Carbapenem-Resistant Organisms in a Critically Ill COVID-19 Patient on Extensively Prolonged Venovenous Extracorporeal Membrane Oxygenation Supportâ€"A Case Report. Microorganisms, 2022, 10, 19.	3.6	4
481	Will There Ever Be Cure for Chronic, Life-Changing Colistin-Resistant Klebsiella pneumoniae in Urinary Tract Infection?. Frontiers in Medicine, 2021, 8, 806849.	2.6	6
482	Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2022, 75, 187-212.	5.8	182
483	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model. Microbiology Spectrum, 2022, 10, e0052522.	3.0	4
484	Efficacy of Combination Therapies for the Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections Based on Meta-Analyses. Antibiotics, 2022, 11, 524.	3.7	7
485	Molecular Tools for the Study of Resistance to Disinfectants. , 0, , .		0
490	In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115712.	1.8	1
491	Mutational Switch-Backs Can Accelerate Evolution of Francisella to a Combination of Ciprofloxacin and Doxycycline. Frontiers in Microbiology, 2022, 13, .	3.5	5
492	Bacterial Toxinâ€Triggered Release of Antibiotics from Capsosomes Protects a Fly Model from Lethal Methicillinâ€Resistant Staphylococcus aureus (MRSA) Infection. Advanced Healthcare Materials, 2022, 11, e2200036.	7.6	3
493	Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach. Antibiotics, 2022, 11, 612.	3.7	4
494	Plantaricin A, Derived from Lactiplantibacillus plantarum, Reduces the Intrinsic Resistance of Gram-Negative Bacteria to Hydrophobic Antibiotics. Applied and Environmental Microbiology, 2022, 88, e0037122.	3.1	3

#	Article	IF	Citations
495	Antibiogram of Urinary Tract Infections and Sepsis among Infants in Neonatal Intensive Care Unit. Children, 2022, 9, 629.	1.5	5
496	A Concise Sar-Analysis of Antimicrobial Cationic Amphipathic Barbiturates for an Improved Activity-Toxicity Profile. SSRN Electronic Journal, 0, , .	0.4	0
498	Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3239.	2.4	10
499	Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis. Frontiers in Microbiology, 0, 13, .	3.5	11
500	Transition Towards Antibiotic Hybrid Vehicles: The Next Generation Antibacterials. Current Medicinal Chemistry, 2023, 30, 104-125.	2.4	4
501	Design and synthesis of hybrid compounds as novel drugs and medicines. RSC Advances, 2022, 12, 19470-19484.	3.6	49
502	Combating biofilm of ESKAPE pathogens from ancient plant-based therapy to modern nanotechnological combinations. , 2022, , 59-94.		1
503	In vitro Investigation of Antibiotic Combinations against Multi- and Extensively Drug-Resistant Klebsiella pneumoniae. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1308-1314.	0.2	0
504	Potential Role of Bioactive Phytochemicals in Combination Therapies against Antimicrobial Activity. Journal of Pharmacopuncture, 2022, 25, 79-87.	1.1	6
505	Clinical Efficacy Protocol of Yinhuapinggan Granules: A Randomized, Double-Blind, Parallel, and Controlled Clinical Trial Program for the Intervention of Community-Acquired Drug-Resistant Bacterial Pneumonia as a Complementary Therapy. Frontiers in Pharmacology, 0, 13, .	3.5	1
507	The Association between Biofilm Formation and Antimicrobial Resistance with Possible Ingenious Bio-Remedial Approaches. Antibiotics, 2022, 11, 930.	3.7	23
508	In vitro activities of antibiotic combinations against mature biofilms of ventilator-associated pneumonia isolates. Future Microbiology, 2022, 17, 1027-1042.	2.0	1
509	Deploying Gold Nanomaterials in Combating Multi-Drug-Resistant Bacteria. ACS Nano, 2022, 16, 10066-10087.	14.6	55
510	Antibiotics in urine from general adults in Shenzhen, China: Demographic-related difference in exposure levels. Science of the Total Environment, 2022, 843, 157070.	8.0	3
511	Activation of a Bacterial Mechanosensitive Channel, MscL, Underlies the Membrane Permeabilization of Dual-Targeting Antibacterial Compounds. Antibiotics, 2022, 11, 970.	3.7	4
512	Recent progress in multifunctional conjugated polymer nanomaterial-based synergistic combination phototherapy for microbial infection theranostics. Coordination Chemistry Reviews, 2022, 470, 214701.	18.8	21
513	Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia. Antibiotics, 2022, 11, 1033.	3.7	1
514	In Vitro Assessment of the Combination of Antibiotics against Some Integron-Harbouring Enterobacteriaceae from Environmental Sources. Antibiotics, 2022, 11, 1090.	3.7	4

#	Article	IF	Citations
515	Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa. Microbiology Spectrum, 0, , .	3.0	1
516	Molecular characterization of multidrug-resistant ESKAPEE pathogens from clinical samples in Chonburi, Thailand (2017â€“2018). BMC Infectious Diseases, 2022, 22, .	2.9	5
517	A concise SAR-analysis of antimicrobial cationic amphipathic barbiturates for an improved activity-toxicity profile. European Journal of Medicinal Chemistry, 2022, 241, 114632.	5.5	5
518	Rapid-killing efficacy substantiates the antiseptic property of the synergistic combination of carvacrol and nerol against nosocomial pathogens. Archives of Microbiology, 2022, 204, .	2.2	4
519	Infectious Disease Consults of Pseudomonas aeruginosa Bloodstream Infection and Impact on Health Outcomes. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
520	Polypharmacology in Clinical Applications: Anti-infection Polypharmacology. , 2022, , 343-374.		0
521	Combination of Isothiocyanates and Antibiotics Increases Susceptibility Against Acinetobacter Baumannii, Escherichia Coli, Klebsiella Pneumoniae, Proteus Mirabilis and Serratia Marcescens. SSRN Electronic Journal, 0, , .	0.4	1
522	Effect of an amalgamated antibiotic and its connection to cyto-genotoxicity and histo-architectural malformations in stinging catfish. Emerging Contaminants, 2022, 8, 381-390.	4.9	1
523	Divalent cation induced reentrant condensation behavior for lipopolysaccharides. Journal of Chemical Physics, 0, , .	3.0	0
524	Current issues and perspectives in antimicrobials use in dental practice. Current Pharmaceutical Design, 2022, 28, .	1.9	3
525	Development of a combination antibiogram for empirical treatments of Pseudomonas aeruginosa at a university-affiliated teaching hospital. Journal of Microbiology, Immunology and Infection, 2022, , .	3.1	0
526	Drug Combinations to Prevent Antimicrobial Resistance: Various Correlations and Laws, and Their Verifications, Thus Proposing Some Principles and a Preliminary Scheme. Antibiotics, 2022, 11, 1279.	3.7	0
527	Impact of Ceftolozaneâ€“Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infectious Diseases and Therapy, 2022, 11, 1965-1980.	4.0	4
528	Defects in DNA doubleâ€strand break repair resensitize antibioticâ€resistant Escherichia coliÂto multiple bactericidal antibiotics. MicrobiologyOpen, 2022, 11, .	3.0	3
529	In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 1451-1457.	2.9	7
530	A Narrative Review Evaluation of Resistance Antibiotics used in Pneumonia. Research Journal of Pharmacy and Technology, 2022, , 4261-4269.	0.8	0
531	Deciphering the Role of Î²-Lactamase Inhibitors, Membrane Permeabilizers and Efflux Pump Inhibitors as Emerging Targets in Antibiotic Resistance. Indian Journal of Microbiology, 0, , .	2.7	0
532	In Vitro and In Vivo Effect of Amikacin and Imipenem Combinations against Multidrug-Resistant E. coli. Tropical Medicine and Infectious Disease, 2022, 7, 281.	2.3	1

#	Article	IF	Citations
534	Antimicrobial stewardship programs in the Intensive Care Unit in patients with infections caused by multidrug-resistant Gram-negative bacilli. Medicina Intensiva (English Edition), 2023, 47, 99-107.	0.2	1
535	Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens. Antibiotics, 2022, 11, 1516.	3.7	2
536	Molecular docking and proteomics reveals the synergistic antibacterial mechanism of theaflavin with Î²-lactam antibiotics against MRSA. Frontiers in Microbiology, 0, 13, .	3.5	2
537	Molecular Characterization and Antibiogram of Acinetobacter baumannii Clinical Isolates Recovered from the Patients with Ventilator-Associated Pneumonia. Healthcare (Switzerland), 2022, 10, 2210.	2.0	6
538	Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults. Infection and Chemotherapy, 2022, 54, 812.	2.3	3
539	The Potential of Antibiotics and Nanomaterial Combinations as Therapeutic Strategies in the Management of Multidrug-Resistant Infections: A Review. International Journal of Molecular Sciences, 2022, 23, 15038.	4.1	16
540	Multicenter Evaluation of the FilmArray Blood Culture Identification 2 Panel for Pathogen Detection in Bloodstream Infections. Microbiology Spectrum, 2023, 11, .	3.0	6
541	Overcoming intrinsic resistance in gram-negative bacteria using small molecule adjuvants. Bioorganic and Medicinal Chemistry Letters, 2023, 80, 129113.	2.2	10
542	A Turtle Disaster: Salmonella enteritidis Cardiovascular Implantable Electronic Device Infection. Open Forum Infectious Diseases, 2022, 9, .	0.9	1
543	Comparison of bacterial suppression by phage cocktails, dualâ€receptor generalists, and coevolutionarily trained phages. Evolutionary Applications, 2023, 16, 152-162.	3.1	5
544	On the use of historical estimates. Statistical Papers, 2024, 65, 203-236.	1.2	0
545	Synthesis and Biological Characterization of Phyto-Fabricated Silver Nanoparticles from Azadirachta indica. Journal of Biomedical Nanotechnology, 2022, 18, 2022-2057.	1.1	5
546	R2-DDI: relation-aware feature refinement for drugâ€“drug interaction prediction. Briefings in Bioinformatics, 2023, 24, .	6.5	4
547	Antibiogram of clinical isolates from primary and secondary healthcare facilities: A step towards antimicrobial stewardship. PLOS Global Public Health, 2022, 2, e0000644.	1.6	1
548	Oral biofilms: Architecture and control. , 2023, , 485-507.		0
549	Phenolics Profiling by HPLC-DAD-ESI/MSn of the Scientific Unknown Polygonum hydropiperoides Michx. and Its Antioxidant and Anti-Methicillin-Resistant Staphylococcus aureus Activities. Plants, 2023, 12, 1606.	3.5	0
550	Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General Hospitals. Infection and Chemotherapy, 2022, 54, 637.	2.3	6
551	Core Elements for Implementing Antimicrobial Stewardship Programs in Korean General Hospitals. Korean Journal of Medicine, 2023, 98, 11-39.	0.3	0

#	Article	IF	Citations
552	Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant Acinetobacter species using checkerboard assay. Journal of Medical Microbiology, 2023, 72, .	1.8	1
553	Antibacterial Carbon Dotsâ€Based Composites. Small, 2023, 19, .	10.0	20
554	Artificial intelligence for drug discovery: Resources, methods, and applications. Molecular Therapy - Nucleic Acids, 2023, 31, 691-702.	5.1	27
555	Fast drug rotation reduces bacterial resistance evolution in a microcosm experiment. Journal of Evolutionary Biology, 2023, 36, 641-649.	1.7	0
556	Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?. Expert Review of Anti-Infective Therapy, 2023, 21, 387-429.	4.4	8
557	CRISPR-Cas9 mediated phage therapy as an alternative to antibiotics. Animal Diseases, 2023, 3, .	1.4	2
558	Antibiogram of Multidrug-Resistant Bacteria Based on Sepsis Onset Location in Korea: A Multicenter Cohort Study. Journal of Korean Medical Science, 2023, 38, .	2.5	1
559	The future of evolutionary medicine: sparking innovation in biomedicine and public health. , 2023, 1, .		11
560	Effect of 2-chloro-N-(4-fluoro-3-nitrophenyl)acetamide in combination with antibacterial drugs against Klebsiella pneumoniae. Anais Da Academia Brasileira De Ciencias, 2023, 95, .	0.8	0
561	Dual-targeted poly(amino acid) nanoparticles deliver drug combinations on-site: an intracellular synergistic strategy to eliminate intracellular bacteria. Journal of Materials Chemistry B, 2023, 11, 2958-2971.	5.8	1
562	Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae. Drug Resistance Updates, 2023, 68, 100961.	14.4	3
563	Comparing the antibacterial efficacy and functionality of different commercial alcohol-based sanitizers. PLoS ONE, 2023, 18, e0282005.	2.5	1
564	Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?. JAC-Antimicrobial Resistance, 2023, 5, .	2.1	1
565	Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives. European Journal of Medicinal Chemistry, 2023, 253, 115326.	5.5	6
566	Design, Synthesis and Biological Evaluation of 7â€Substitutedâ€1,3â€diaminopyrrol[3,2â€f]quinazolines as Potential Antibacterial Agents. ChemMedChem, 0, , .	3.2	0
567	Drug Resistance: An Incessant Fight against Evolutionary Strategies of Survival. Microbiology Research, 2023, 14, 507-542.	1.9	2
568	Aminoglycosides for the Treatment of Severe Infection Due to Resistant Gram-Negative Pathogens. Antibiotics, 2023, 12, 860.	3.7	7
569	Comparative inÂvitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis. Journal of Chemotherapy, 2023, 35, 700-706.	1.5	0

#	Article	IF	Citations
570	Benefits of Manuka Honey in the Management of Infectious Diseases: Recent Advances and Prospects. Mini-Reviews in Medicinal Chemistry, 2023, 23, 1928-1941.	2.4	1
571	Rapid In Vitro Assessment of Antimicrobial Drug Effect Bridging Clinically Relevant Pharmacokinetics: A Comprehensive Methodology. Pharmaceutics, 2023, 15, 1671.	4.5	0
572	Simple and Efficient Synthesis of 3-Aryl-2-oxazolidinone Scaffolds Enabling Increased Potency toward Biofilms. Molecular Pharmaceutics, 2023, 20, 3484-3493.	4.6	4
573	Bifunctional antibiotic hybrids: A review of clinical candidates. Frontiers in Pharmacology, 0, 14, .	3.5	2
574	Mutators can drive the evolution of multi-resistance to antibiotics. PLoS Genetics, 2023, 19, e1010791.	3.5	3
575	Post-COVID-19 cavitary lung lesion due to Aspergillus flavus and Enterobacter cloacae in a patient suffering from COVID-19 pneumonia â€“ a case report. Access Microbiology, 2023, 5, .	0.5	0
576	Nanocomposite orthopaedic bone cement combining long-acting dual antimicrobial drugs. , 2023, 153, 213538.		3
577	Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Annals of Clinical Microbiology and Antimicrobials, 2023, 22, .	3.8	0
578	Molecular phylogeny, Sequence-based drug design, Docking built virtual screening, dynamics simulations, and ADMET properties of thiazolino 2-pyridone amide derivatives as an inhibitor of Chlamydia trachomatis and SARS-CoV-2 protein. Turkish Computational and Theoretical Chemistry, 2024, 8, 10-39.	0.5	0
579	Collateral sensitivity: An evolutionary tradeâ€off between antibiotic resistance mechanisms, attractive for dealing with drugâ€resistance crisis. Health Science Reports, 2023, 6, .	1.5	0
581	Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical Infectious Diseases, 0, , .	5.8	105
582	Interpreting Randomized Controlled Trials. Cancers, 2023, 15, 4674.	3.7	0
583	Enhanced Bactericidal Effects and Drug Delivery with Gentamicin-Conjugated Nanoparticles. Journal of Cluster Science, 2024, 35, 371-390.	3.3	1
584	Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review. Antibiotics, 2023, 12, 1262.	3.7	2
585	Analysis of C-reactive Protein Level as a Monitoring Tool in Patients with Odontogenic Space Infection: A Prospective Clinical Study. Journal of Oral Health and Community Dentistry, 2023, 17, 37-43.	0.1	0
586	Point prevalence probing of antimicrobial prescription patterns from a developing country. Expert Review of Anti-Infective Therapy, 2023, 21, 1269-1276.	4.4	0
587	Management strategies for severe Pseudomonas aeruginosa infections. Current Opinion in Infectious Diseases, 2023, 36, 585-595.	3.1	1
588	Six-year analysis of key monitoring for bacterial strain distribution and antibiotic sensitivity in a hospital. World Journal of Clinical Cases, 0, 11, 7294-7301.	0.8	0

#	Article	IF	Citations
589	Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis. Antibiotics, 2023, 12, 1581.	3.7	0
590	Monitoring hostâ€“pathogen interactions using chemical proteomics. RSC Chemical Biology, 2024, 5, 73-89.	4.1	0
591	Biogenic carbon dots: a novel mechanistic approach to combat multidrug-resistant critical pathogens on the global priority list. Journal of Materials Chemistry B, 2023, 12, 202-221.	5.8	2
592	A metagenomic analysis for combination therapy of multiple classes of antibiotics on the prevention of the spread of antibiotic-resistant genes. Gut Microbes, 2023, 15, .	9.8	0
593	Nano-ciprofloxacin/meropenem exhibit bactericidal activity against Gram-negative bacteria and rescue septic rat model. Nanomedicine, 2023, 18, 1553-1566.	3.3	0
594	Peripartum Sepsis. Current Obstetrics and Gynecology Reports, 2023, 12, 209-214.	0.8	0
596	Mechanistic Approach of Effective Combination of Antibiotics Against Clinical Bacterial Strains Having New Delhi Metallo-Beta-Lactamase Variants and Functional Gain Laboratory Mutant. Current Microbiology, 2024, 81, .	2.2	0
597	Novel Hydroxamic Acids Containing Aryl-Substituted 1,2,4- or 1,3,4-Oxadiazole Backbones and an Investigation of Their Antibiotic Potentiation Activity. International Journal of Molecular Sciences, 2024, 25, 96.	4.1	0
598	Clinical outcomes in combination versus mono antibiotic therapy in ICU admitted patients with a suspected infection - A substudy of the DIANA study. Journal of Critical Care, 2024, 80, 154501.	2.2	0
599	Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study. Critical Care, 2024, 28, .	5.8	0
600	Copper(II)-photocatalyzed Hydrocarboxylation of Schiff bases with CO ₂ : antimicrobial evaluation and in silico studies of Schiff bases and unnatural Î±-amino acids. Journal of Biomolecular Structure and Dynamics, 0, , 1-14.	3.5	0
601	Prediction of the synergistic effect of antimicrobial peptides and antimicrobial agents via supervised machine learning. BMC Biomedical Engineering, 2024, 6, .	2.6	0
602	Assessment of Health Care Compliance in Managing Pseudomonas Aeruginosa in Urinary Tract Infection Using Machine Learning Techniques. , 2023, , .		0
603	Optimal individualized treatment rule for combination treatments under budget constraints. Journal of the Royal Statistical Society Series B: Statistical Methodology, 0, , .	2.2	0
604	Laboratory Evolution of Antimicrobial Resistance in Bacteria to Develop Rational Treatment Strategies. Antibiotics, 2024, 13, 94.	3.7	0
605	Acinetobacter baumannii. , 2024, , 853-877.		0
606	Antimicrobial Stewardship in the Management of Multidrug-Resistant Gram-Negative Bacteria Infections. , 0, , .		0
607	Colistin monotherapy or combination for the treatment of bloodstream infection caused by Klebsiella pneumoniae: a systematic review and meta-analysis. BMC Infectious Diseases, 2024, 24, .	2.9	0

#	Article	IF	Citations
608	Recent Advances in Understanding the Molecular Mechanisms of Multidrug Resistance and Novel Approaches of CRISPR/Cas9-Based Genome-Editing to Combat This Health Emergency. International Journal of Nanomedicine, 0, Volume 19, 1125-1143.	6.7	0
609	Combating antimicrobial resistance: the silent war. Frontiers in Pharmacology, 0, 15, .	3.5	0
610	Within-species variability of antibiotic interactions in Gram-negative bacteria. MBio, 2024, 15, .	4.1	0
611	Study of Empiric Antibiotic Prescription Patterns and Microbiological Isolates in Hemodynamically Stable and Unstable ICU Patients With Community-Acquired Sepsis. Journal of Intensive Care Medicine, 0, , .	2.8	0
612	Current developments and prospects of the antibiotic delivery systems. Critical Reviews in Microbiology, 0, , 1-40.	6.1	0
613	Wild-Type AmpC Beta-Lactamase-Producing Enterobacterales Are a Risk Factor for Empirical Treatment Failure in Patients with Bloodstream Infection. Diseases (Basel, Switzerland), 2024, 12, 52.	2.5	0
614	Silver nanoparticles synthesized from Pseudomonas aeruginosa pyoverdine: Antibiofilm and antivirulence agents. Biofilm, 2024, 7, 100192.	3.8	0
615	Antibiotic heteroresistance in Klebsiella pneumoniae: Definition, detection methods, mechanisms, and combination therapy. Microbiological Research, 2024, 283, 127701.	5.3	0
616	Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions. Heliyon, 2024, 10, e27984.	3.2	0
617	Novel Î²-lactam-Î²-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study. Journal of Infection and Chemotherapy, 2024, , .	1.7	0